Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PIM activity in tumours: A key node of therapy resistance.

Literature DB >> 29111105

PIM activity in tumours: A key node of therapy resistance.

Richard J Rebello¹, Alisée V Huglo², Luc Furic³.

Abstract

The PIM kinases are proto-oncogenes which have been shown to facilitate cell survival and proliferation to drive malignancy and resistance post-therapy. They are able to suppress cell death signals, sustain PI3K/AKT/mTORC1 pathway activity and regulate the MYC oncogenic program. Recent work has revealed PIM kinase essentiality for advanced tumour maintenance and described tumour sensitivity to small molecule inhibitors targeting PIM kinase in multiple malignancies.

Entities: Disease Gene

Keywords: AKT; Breast; Cancer; MYC; PIM; Prostate; mRNA translation; mTOR

Mesh：

Substances：

Year: 2017 PMID： 29111105 DOI： 10.1016/j.jbior.2017.10.010

Source DB: PubMed Journal: Adv Biol Regul ISSN： 2212-4926

Keyword Cloud
Cited

12 in total

Review 1. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors: Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal: Signal Transduct Target Ther Date: 2020-01-31

2. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors: Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal: Clin Cancer Res Date: 2018-10-16 Impact factor: 12.531

Review 3. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors: Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal: Signal Transduct Target Ther Date: 2022-06-24

4. Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.

Authors: Tatevik R Broutian; Bo Jiang; Jingfeng Li; Keiko Akagi; Shanying Gui; Zhengqiu Zhou; Weihong Xiao; David E Symer; Maura L Gillison
Journal: Cancer Lett Date: 2020-01-17 Impact factor: 8.679

5. Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC.

Authors: Gillian Moore; Clara Lightner; Samira Elbai; Lauren Brady; Siobhan Nicholson; Ronan Ryan; Katie E O'Sullivan; Kenneth J O'Byrne; Carmen Blanco-Aparicio; Sinead Cuffe; Michael O'Neill; Susan Heavey; Stephen P Finn; Kathy Gately
Journal: Cancers (Basel) Date: 2021-04-29 Impact factor: 6.639

Review 6. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.

Authors: Aziz Ur Rehman Aziz; Sumbal Farid; Kairong Qin; Hanqin Wang; Bo Liu
Journal: Biomolecules Date: 2018-02-04

7. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.

Authors: Sabina Luszczak; Benjamin S Simpson; Urszula Stopka-Farooqui; Vignesh Krishna Sathyadevan; Lina M Carmona Echeverria; Christopher Kumar; Helena Costa; Aiman Haider; Alex Freeman; Charles Jameson; Marzena Ratynska; Imen Ben-Salha; Ashwin Sridhar; Greg Shaw; John D Kelly; Hayley Pye; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal: Sci Rep Date: 2020-09-01 Impact factor: 4.379